Ibrutinib was a breakthrough when it was first approved to treat R/R MCL in 2013, and a year later for patients with at least 1 prior treatment for chronic lymphocytic leukemia. However, its ...

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...

H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR ...

Findings could be practice changing if proven prospectively, experts say ...

While rare, secondary cancers after CAR T-cell therapy have been reported, leading the FDA to mandate boxed warnings on all approved therapies. In a first, targeted therapy was used to treat a T-cell ...

In a first-in-human study, researchers at The University of Texas MD Anderson Cancer Center observed strong responses and early signs of antitumor activity in patients with difficult-to-treat ...

MB-105, a CD5-targeted CAR-T cell therapy, is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...

Please provide your email address to receive an email when new articles are posted on . Most patients with B-cell lymphomas who relapsed after CAR T-cell therapy responded to the novel, ...

Relapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often resist standard therapy. Patients with these lymphomas may require stem cell ...